Skip to main content
Equibles
JNJ logo

JNJ · Johnson & Johnson

Track JNJ — free

Use JNJ with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about JNJ

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$260.35 -1.73 (-0.66%) At close · Aug 14
Market Cap
$627.42B
Shares
2.41B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$260.35 Open$260.65 Day$259.16–261.71 52W close$174.16–267.24 Avg vol 30d7.6M Short int25.4M · 1.1% float · 3.0d Short vol54% Last earningsJul 15, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 23

Up next

Next earnings call
Oct 14, 2026 Est · unconfirmed · in 8 wks
FQ3-27 quarter ends
~Oct 3, 2026 Est
Latest filing: 10-Q
filed Jul 23, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Research

      our published analysis of this company

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very Low
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +13%
      above
      Price vs 50-day avg +4%
      above
      RSI (14) 55
      neutral
      MACD trend Negative
      52-week position 93%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +3%
      trailing
      6-month return +6%
      trailing
      YTD return +26%
      this year
      Relative strength −8%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $251 › 200d $230 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +216 funds added
      Insider flow Distributing
      Net -$57.0M over 90 days · 100% sells
      Short interest Falling
      1.05% of float · ▼ -7.4% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      4,607 holders — near 3-yr high, broad support
      Squeeze score 46
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +6%
      Y/Y
      Gross margin 68%
      contracting
      EPS growth +91%
      Y/Y
      Free cash flow $19.7B
      Valuation P/E 30.2
      below peers
      Buyback $5.0B
      authorized
      Balance sheet $28.2B
      net debt
      Quant / Vol
      risk profile
      Very Low
      Volatility 18%
      annualized · 1-yr
      Max drawdown −11%
      past year
      ATR 2.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 15, 2026
      Adjusted Operational Sales Change vs. Prior Year · Full-year 2026 Non-GAAP 6.2% – 6.8%
      Operational Sales · Full-year 2026 Non-GAAP $100.3B – $100.9B
      Operational Sales Change vs. Prior Year · Full-year 2026 Non-GAAP 6.5% – 7.1%
      Estimated Reported Sales · Full-year 2026 $100.8B – $101.4B
      Adjusted Operational EPS (Diluted) · Full-year 2026 Non-GAAP $11.50 – $11.65
      Estimated Reported Sales Change vs. Prior Year · Full-year 2026 7% – 7.6%
      Adjusted EPS (Diluted) Change vs. Prior Year · Full-year 2026 Non-GAAP 7.5% – 8.9%
      Adjusted EPS (Diluted) · Full-year 2026 Non-GAAP $11.60 – $11.75
      Adjusted Operational EPS (Diluted) Change vs. Prior Year · Full-year 2026 Non-GAAP 6.6% – 8%
      Prior guidance period ended · from the Earnings Call filed Jul 31, 2025
      Operational sales growth · full year 2025 4.8% – 5.3%
      Operational sales growth · full year 2025 (reported) 3.5% – 4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +13% Bullish
      Price vs 50-day avg
      +4% Bullish
      RSI (14)
      55 Neutral
      MACD trend
      Negative Bearish
      52-week position
      93% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $251 › 200d $230 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +216 funds added
      Insider flow Distributing
      Net -$57.0M over 90 days · 100% sells
      Short interest Falling
      1.05% of float · ▼ -7.4% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      4,607 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $174 Now $260 · 93% Range high $267
      vs 200-day avg +13% vs 50-day avg +4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted Operational Sales non-GAAP 6.1% Q4 2025 —
      Operational Sales non-GAAP 7.1% Q4 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - General — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      JNJ
      Johnson & Johnson
      this stock
      		$627.42B +25.8% +6.0% 30.2 1.1%
      LLY
      ELI LILLY & Co
      		 $1.11T +9.8% +44.7% 39.6 1.0%
      ABBV
      AbbVie Inc.
      		 $442.24B +9.2% +8.6% 70.7 1.3%
      MRK
      Merck & Co., Inc.
      		 $335.14B +29.1% +1.3% 108.7 1.1%
      NVS
      Novartis AG
      		 $286.78B +9.4% — — 0.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      4,607
      % held
      75.9%
      Net QoQ
      +25.5M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,731
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      25.4M
      Days to cover
      3.0d
      Change
      -2.0M sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      4.0K
      Value
      $1.0M
      As of
      Jul 13, 2026
      View
      Off-Exchange
      Off-exchange %
      46.0%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$57.0M
      Buyers / Sellers
      0 / 4
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Thomas H. Kean
      Amount
      $1.0K–$15.0K
      Traded
      Jun 29, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $94.2B
      Net income (FY)
      $26.8B
      EPS diluted
      $11.03
      View
      Buybacks
      Authorized
      $5.0B
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $32.2M
      Shares
      123.3K
      Filed
      Aug 13, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 9, 2026
      Last call
      Aug 14, 2026
      View
      Investor Relations
      Latest news
      Johnson & Johnson to Participate…
      Published
      Aug 10, 2026
      Upcoming events
      2
      View

      Performance

      5D 20D 120D MTD YTD
      JNJ +0.4% +2.9% +5.9% +1.6% +25.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +0.0% -1.6% -7.9% -2.4% +12.0%

      Capital returns

      Latest dividend
      $1.34 / share · ex May 26, 2026
      Declared · upcoming
      $1.34 / share · ex Aug 25, 2026
      Raised 3.1%
      Paid (TTM)
      $5.24 / share · 4 payouts
      Dividend yield (TTM, derived)
      2.01%
      Buyback program · as of Sep 14, 2022
      Authorized
      $5.00B
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 200406 CUSIP 478160104 13F (30d) 3922 filings 3799 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)